SCHEMBL21484882

SCHEMBL21484882

N#C/C(=C\c1ccc(O)c(Cl)c1)C(=O)Nc1nc(-c2ccccc2)cs1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 4/20 0.53
ERBB2 P04626 3/20 0.53
LMNA P02545 3/20 0.51
MEN1 O00255 3/20 0.51
MAPT P10636 3/20 0.51
KMT2A Q03164 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
ALDH1A1 P00352 2/20 0.51
MAPK1 P28482 2/20 0.51
KDM4E B2RXH2 1/20 0.51
PSMD14 O00487 1/20 0.51
RGS12 O14924 1/20 0.51
GMNN O75496 1/20 0.51
TP53 P04637 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
PKM P14618 1/20 0.51
HPGD P15428 1/20 0.51
ALOX15 P16050 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21484629 0.91 EGFR (0.62) EGFRERBB2LMNAMEN1MAPT
SCHEMBL21484775 0.90 MRE11 (0.51) LMNAMEN1MAPTKMT2ASMN1; SMN2
SCHEMBL21484912 0.89 MEN1 (0.52) EGFRERBB2LMNAMEN1MAPT
SCHEMBL21484888 0.89 EGFR (0.60) EGFRERBB2LMNAMEN1MAPT
SCHEMBL21505433 0.89 EGFR (0.51) EGFRERBB2LMNAMEN1MAPT
SCHEMBL21484916 0.89 CSNK2A1 (0.63) EGFRERBB2LMNAMEN1MAPT
SCHEMBL28514954 0.89 EGFR (0.51) EGFRERBB2LMNAMEN1MAPT
SCHEMBL21484792 0.89 EGFR (0.53) EGFRERBB2LMNAMEN1MAPT
SCHEMBL21484699 0.89 MRE11 (0.57) EGFRERBB2LMNAMEN1MAPT
SCHEMBL21505900 0.87 MEN1 (0.49) EGFRERBB2LMNAMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
EP-3556755-B1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2021-11-17 EP disclosed
EP-3556755-B1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2021-11-17 EP disclosed
CN-112313229-A Substituted aminothiazoles as inhibitors of nucleases 马萨里克大学 2021-02-02 CN disclosed
WO-2019201865-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
EP-3556755-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed
EP-3556755-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases RNASEH1, DNASE1, FEN1 EGFR 1661/4885ERBB2 2095/4885LMNA 522/4885
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES RNASEH1, DNASE1, FEN1 EGFR 1661/4885ERBB2 2095/4885LMNA 522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.